You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Syngene reported second-quarter revenue of 833 crores, up 13% sequentially, operating EBITDA of 147 crores at an 18% margin, and profit after tax of 32 crores. It signed its first Bayview Biologics manufacturing agreement and maintained guidance of mid-20 EBITDAs excluding forex losses.
Illustrative technical + ownership context — a signal mix, not investment advice.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XBOM:SYNGENE | +6.6% | +15.9% | -3.9% | +10.5% | -31.7% |
Share classes and depositary receipts can have different prices and dividends.
| Ex-dividend date | Amount per share |
|---|---|
| 2026-06-25 | 1.25 INR |
| 2025-06-27 | 1.25 INR |
| 2024-06-28 | 1.25 INR |
| 2023-06-30 | 1.25 INR |
| 2022-06-30 | 1.00 INR |
| 2019-07-16 | 0.50 INR |
| 2017-07-20 | 0.50 INR |
| 2016-03-17 | 0.50 INR |
No upcoming investor events are listed for this company yet.
